Research & Development
BioPorto submits FDA application for The NGAL Test in paediatric patients
16 May 2019 -

BioPorto A/S (CPH:BIOPOR) announced on Wednesday that the company has submitted an application to the US Food and Drug Administration (FDA) for regulatory clearance of The NGAL Test in the US for risk assessment of acute kidney injury (AKI) in children under the age of 21.

According to BioPorto, its application is based on a retrospective set of samples of urinary NGAL in children originally tested with the BioPorto NGAL ELISA test in 2014. These samples were originally obtained as part of the Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology (AWARE) study by Ahmad Kaddourah, M.D, Rajit K. Basu, M.D, Sean M. Bagshaw, M.D and Stuart L. Goldstein, M.D. It involved 4,683 patients from 32 paediatric ICUs across Asia, Australia, Europe and North America. Of the patients evaluated, 1,261 developed AKI and 543 patients developed severe AKI.

Under this study, BioPorto has re-tested a subset of the original samples using The NGAL Test, its new automated assay. These results were compared to the original adjudicated AKI status to demonstrate The NGAL Test's ability to predict the risk of patients developing moderate to severe AKI. The NGAL Test results were also compared to the original ELISA result, demonstrating the bridging performance of the two test methodologies.

In the newly submitted data, The NGAL Test had a sensitivity of 65.0% and specificity of 81.8% with a negative predictive value of 95.4%. BioPorto believes these are strong results that support the potential of The NGAL Test to be a clinically valuable tool to help clinicians better assess AKI risk in critically ill children.

The NGAL Test for paediatric risk assessment has been granted designation as a Breakthrough Device by FDA, identifying that it may 'provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions'. Receiving this designation means that BioPorto's application will receive priority review, reducing the expected FDA review period from 90 days to 45 days. As a result, a decision regarding the application could be received before the end of July 2019, assuming a standard FDA review timeline for Breakthrough Devices.

BioPorto clarified that this submission of the FDA application does not alter its financial guidance for 2019.

BioPorto is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies.